EBIT at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s EBIT?
- Monte Rosa Therapeutics, Inc. (GLUE) reported EBIT of -$50.03M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s EBIT changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s EBIT decreased by 213.6% year-over-year, from $44.04M to -$50.03M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s EBIT?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s EBIT has grown at a -9.4% compound annual growth rate (CAGR), from -$72.88M to -$54.21M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.